| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5689309 | European Urology | 2017 | 4 Pages |
Abstract
According to data from longer follow-up, enzalutamide continued to provide benefit over placebo in patients with metastatic castration-resistant prostate cancer.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Tomasz M. Beer, Andrew J. Armstrong, Dana Rathkopf, Yohann Loriot, Cora N. Sternberg, Celestia S. Higano, Peter Iversen, Christopher P. Evans, Choung-Soo Kim, Go Kimura, Kurt Miller, Fred Saad, Anders S. Bjartell, Michael Borre, Peter Mulders,